Foundation Medicine Presents New Data at the 2016 USCAP Annual Meeting Underscoring Importance of Comprehensive Genomic Profiling in Cancer Care
Latest Data Demonstrate the Clinical Utility of FoundationOne® in Brain and Breast Cancers to Complement Standard Pathology Practices in Improving Oncology Patient Outcomes with Targeted Therapy
"We are encouraged by the latest data presented amongst the global leaders and top minds in the pathology field at USCAP," said Jeffrey S. Ross M.D., medical director of
Three of the posters presented at the event focused on cancers with diverse, clinically relevant alterations, many of which are undetectable with standard screening, and represent indications with unmet clinical need, including refractory and metastatic breast cancer, triple negative breast cancer (TNBC) and adult and pediatric brain tumors. Results from all three data sets point to the importance of comprehensive genomic profiling to potentially influence and personalize treatment and guide the selection of approved targeted therapies or access to novel therapies that are being investigated in clinical trials.
Key Data Highlights:
The poster presentation titled, "Pangenomic Analysis of BRAF Genomic Alterations Across All Types of Brain Tumors Reveals Expanded Opportunities for Targeted Therapies," by
- 142 (4.8 percent) brain tumors featured BRAF alterations including base substitutions (70 percent), fusions (25 percent) and rare amplifications and other alterations types (5 percent). Genomic alterations in BRAF are widely distributed in brain tumors with base substitutions primarily seen in high-grade gliomas and BRAF fusions in low grade gliomas
- The presentation demonstrated that BRAF base substitutions and fusions can be successfully targeted with anti-BRAF and anti-MEK targeted therapies
Preliminary findings outlined in the poster presentation titled, "Genomic Alterations of MCL1 is a Predictive Biomarker of Triple Negative Status and Therapy Response in Breast Cancer," led and presented by
- MCL1 amplification is a frequent feature in advanced stage and high grade breast cancer, and MCL1 amplified breast cancer is very seldom ERBB2 co-amplified
- Of the MCL1 amplified breast cancer cases, 88 percent were high grade and 98 percent were stage IV at the time of sequencing
- Of the 200 MCL1 amplified breast cancer patients, 12 (6 percent) were ERBB2 (HER2) amplified
- Clinical observation across several case studies suggest that treatment with targeted therapies including sorafenib and vorinostat in heavily pre-treated MCL1 amplified breast cancer may be correlated with clinical benefit
- These preliminary findings suggest that MCL1 amplified TNBC may benefit from combination targeted therapy, and warrant further investigation in a prospective clinical trial
Consistent with the other two data sets, the findings in the poster presentation titled, "The Detection of IHC-/FISH- ERBB2 Non-Amplification Mutations in 5,606 Cases of Refractory and Metastatic Breast Cancer: an Emerging Opportunity for anti-HER2 Targeted Therapies," led by
- ERBB2mut are responsible for nearly 20 percent of ERBB2 alterations in metastatic breast cancer, though such mutations are not detectable by routine IHC and FISH slide-based HER2 tests
- 698 (12.5 percent) featured ERBB2 alterations, 596 (10.6 percent) featured ERBB2 amplifications (ERBB2amp) and 137 (2.4 percent) featured ERBB2mut
- Evidence that ERBB2mut driven mBC are responsive to anti-HER2 targeted therapies is steadily accumulating
About
Cautionary Note Regarding Forward-Looking Statements for
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of comprehensive genomic profiling, including FoundationOne, to identify genomic alterations and improve patient outcomes; the clinical relevance of comprehensive genomic profiling in cancer treatment, coverage and payment decisions by payors and the development of targeted therapies; and the potential of genomic profiling to assist pathologists. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that
View source version on businesswire.com: http://www.businesswire.com/news/home/20160316005237/en/
Media Contact:
dan@purecommunicationsinc.com
or
Investor Contact:
ir@foundationmedicine.com
Source:
News Provided by Acquire Media